Vigmed receives CE mark approval for their SWiNG product

Vigmed announced today that they have received the CE mark for commercial sales
of their new product Vigmed® SWiNG.
The SWiNG products add to Vigmed’s range of unique and patented safety devices
developed by the company in their continuous efforts to eliminate the risks and
hazards of needlestick injuries.

SWiNG is the first safety cover for hypodermic needles that once activated
automatically prevents needlestick injuries, both during and after injection.

“This is a major milestone for both our company and for medical staff around the
world. The launch of this product comes at a timely moment with the focus on
current Ebola-crisis in mind”, says Vigmed CEO Finn Ketler. “We strive to make
the workplace of medical staff a safer place, and offering this safety device to
the market will further contribute to this effort, as well as adding safety to
one of the most common medical procedures in the world.”

The CE-mark enables Vigmed to immediately increase their presence in the market.

“Our distributors can now start introducing this line to their markets and we
are confident the products will be positively received by both our customers and
end users”, says Vigmed Sales Director Europe, Mike Dooley.
For further information contact:

CEO, Finn Ketler +46 42 600 5311 or Director of Quality Assurance & Regulatory
Affairs, Ola Lindau +46 42 600 5315
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20
employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm
(ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the
Company’s Certified Advisor.

Additional information such as company description, a video presentation and
risk factors can be found on Vigmed’s website: www.vigmed.com/investor